The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
NCT ID: NCT05562167
Last Updated: 2025-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
75 participants
INTERVENTIONAL
2023-03-31
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response
NCT02797184
Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF
NCT02256345
Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)
NCT02713126
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
NCT01932606
Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF
NCT02742129
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Consent: All study procedures will be reviewed with the participants before the investigators obtain written informed consent. Consent includes giving permission for the investigators to review their medical records.
2. Blood Samples: Participants will report to the Clinical Translational Research Unit (CTRU) at Washington University Medical Center after an overnight (10-12 hour) fast. An intravenous catheter will be placed to facilitate blood sampling 5 times during the visit. The first blood sample (time 0) will be for screening/phenotyping laboratories: NT-proBNP, chemistries (including K+), glucose, and creatinine (for estimation of glomerular filtration rate).
3. Urine Pregnancy Test: Women of child-bearing age will have a urine pregnancy test.
4. Physical Exam: Participants will have a brief history and physical examination. Heart rate (HR) and blood pressure (BP) will be taken.
5. Resting Echocardiogram with contrast: Participants will also undergo a standard 2D Doppler, tissue Doppler and strain imaging echocardiography to quantify left ventricular structure and function.
6. Questionnaires: Participants will complete a medical history form, the Kansas City Cardiomyopathy Questionnaire (KCCQ), and Minnesota Living with Heart Failure Questionnaire (MLHFQ).
7. NYHA classification will be determined.
8. Blood Pressure and Heart Rate: BP and HR will be measured at time 0 and hourly for 4 hours.
9. Breath Nitric Oxide: Participants will exhale into a tube attached to a portable electrochemical analyzer (NIOX VERO, Aerocrine Inc., Morrisville, NC) following the American Thoracic Society/European Respiratory Society guidelines at time 0 and hourly for 4 hours.
10. Blood sampling for NO3- and NO2-: Participants will have blood drawn (20mL or about 1.5 tbsp) through their previously placed intravenous catheter at time 0 and hourly for 4 hours.
11. Exercise Test - Maximal Muscle Power: After 2 hours, knee extensor muscle power will be determined using a Biodex isokinetic dynamometer (Biodex Medical Systems, Shirley, NY).
12. Exercise Test - Aerobic Capacity: After 10 min of recovery from the muscle power testing, peak oxygen consumption (V̇O2peak) will be determined with an incremental treadmill exercise test to volitional fatigue.
13. Randomization: Participants will be randomized to the KNO3 or placebo arm in a double-blind fashion, stratified by sex and ischemic/nonischemic status.
14. Participants will be instructed to take the medication every day at the same time of the AM. Participants will be instructed to take the medication with food.
Visit 2: Acute Dose Study Day
15. Baseline blood K+ and eGFR levels. As with Visit 1, participants will report to the CTRU fasted (and not having used mouthwash for 24 hours) and have a physical exam and blood drawn for creatinine and K+.
16. Ingestion of a gelatin capsule containing either 10 mmol KNO3 or placebo, per the randomization scheme.
17. HR, BP, plasma NO3- and NO2- , and breath NO: As in Visit 1, HR, BP, plasma NO3- and NO2- , and breath NO will be measured at time 0 (prior to ingestion of a single gelatin capsule) and thereafter hourly for 4 h after the participant ingests a single gelatin capsule containing either 10 mmol KNO3 or placebo, per the randomization scheme.
18. Exercise Test - Maximal Muscle Power: After 2 hours, knee extensor muscle power will be determined using a Biodex isokinetic dynamometer.
19. Exercise Test - Aerobic Capacity: After 10 min of recovery from the muscle power testing, peak oxygen consumption (V̇O2peak) will be determined with an incremental treadmill exercise test to volitional fatigue.
20. Questionnaires: Participants will complete a medical history form, the Kansas City Cardiomyopathy Questionnaire (KCCQ), and Minnesota Living with Heart Failure Questionnaire (MLHFQ).
21. Intervention: After completion of Visit 2, participants will be given a 6-week course of 10 mmol KNO3 or placebo (such that the participants will be given the same medication (nitrate or placebo) that they were given in the Acute Dose Study), one capsule for each day, to be taken p.o.. Participants will be instructed to not use mouthwash before ingesting the study capsules and to not change their diet or level of physical activity during the study (in particular, to not begin or cease an exercise program while enrolled in the study).
Visit 3: 6-Week Dose
22. Procedures: The procedures for this visit will be identical to those described for Visit 2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Potassium Nitrate (KNO3) treatment arm
10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
KNO3
10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
Placebo-controlled arm
10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Placebo
10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KNO3
10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
Placebo
10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable medical therapy, defined by no addition or removal (or change of more than 100 percent) of the following: beta-adrenergic blockade and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB or aldosterone antagonists) or ARNI (ARB + sacubitril) for 60 days.
Exclusion Criteria
* Pharmacologic, organic nitrate therapy within the last 3 months
* Major orthopedic, psychiatric, neurological, or other conditions that would hinder the ability to complete the exercise tests
* Estimated glomerular filtration rate less than 45 mL/min on screening clinical laboratories
* Systolic blood pressure less than 90mmHg or greater than 180mmHg at screening; Diastolic blood pressure less than 40mmHg or greater than 100mmHg at screening
* Previous adverse reaction to nitrate necessitating withdrawal of therapy; Treatment with phosphodiesterase inhibitors within the last 3 months (patient must also be willing to not take them for the duration of the trial)
* Ejection fraction greater than or equal to 45%
* Primary hypertrophic cardiomyopathy; Infiltrative cardiomyopathy (e.g., amyloid); Active myocarditis; Complex congenital heart disease;
* Active collagen vascular disease;
* Percutaneous coronary intervention, new bi-ventricular pacing, or coronary artery bypass grafting within the past 3 months
* Valvular heart disease with severe regurgitation or stenosis of any valve
* Acute or chronic severe liver disease as evidenced by encephalopathy or variceal bleeding
* Terminal disease (other than heart failure) with expected survival less than 1 y
* Enrollment in another therapeutic trial during the period of the study
* Pregnant women; Postmenopausal women taking exogenous estrogen replacement therapy
* Patients requiring exogenous oxygen at rest or during exercise
* Patients with active angina or ischemia due to epicardial coronary disease
* Patients taking xanthine oxidase inhibitors will be excluded
* Individuals taking proton pump inhibitors, antacids will be asked to hold these medications for the duration of the study if approved by his/her physician.
19 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda R Peterson, MD
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Lauren K Park, PhD
Role: STUDY_DIRECTOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington University School of Medicine
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202204141
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.